Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | TP53 | P04637 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PNLIP | P16233 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783366 | 0.85 | GLA (0.71) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL2091569 | 0.85 | GLA (0.71) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL4117977 | 0.84 | TP53 (0.69) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL4105488 | 0.84 | ALDH1A1 (0.70) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL24047280 | 0.83 | GLA (0.69) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL2095026 | 0.83 | GLA (0.69) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL5188506 | 0.83 | GLA (1.00) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL19223060 | 0.82 | KMT2A (0.73) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL31185151 | 0.81 | GLA (0.67) | GLAALDH1A1KMT2ATP53LMNA | |
| SCHEMBL31185167 | 0.81 | GLA (0.67) | GLAALDH1A1KMT2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2020-10-15 | — | — | US | disclosed |
| EP-3705481-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | Rui Jin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine (CN) | 2020-09-09 | — | — | EP | disclosed |
| WO-2019196111-A1 | ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX | 上海交通大学医学院附属瑞金医院 | 2019-10-17 | — | — | WO | disclosed |
| EP-2236494-B1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD KK (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2236494-A1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1901745-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1898917-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1896029-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006135644-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135719-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135713-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | CHRM2, CHRM3, CHRM1 | GLA 2967/4885ALDH1A1 1423/4885KMT2A 1869/4885 |
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | WEE1, ABCG2, WEE2 | GLA 2956/4885ALDH1A1 947/4885KMT2A 1682/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | GLA 4138/4885ALDH1A1 412/4885KMT2A 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.